Ann: Kazia Half Year Accounts and Chairman's letter, page-97

rikki, Iain Ross stated in the Kazia Chaiman's letter 20 February 2020 that " We expect to see initial data out of several of these studies during the year ahead. If they too report positive data, it will give us even greater confidence in the therapeutic potential of paxalisib",
IMO the Paxalisib drug value may continue to increase as positive data is progressively released during this year from our other drug trials.

Iain Ross also stated that " Put simply, on all available evidence, paxalisib works. Almost no cancer drug is curative, but the ability to delay the progress of disease is extremely material to patients, clinicians, regulators, and payors.",
The shareholders may have further confirmation that paxalisib works, with updated interim data from our Glioblastoma trial at ACCR in 2 months.

Regards.